Hepatocellular carcinoma

  title={Hepatocellular carcinoma},
  author={Alejandro Forner and Josep M. Llovet and Jordi Bruix},
  journal={The Lancet},
Localized and systemic approaches to treating hepatocellular carcinoma.
  • J. Knox, S. Cleary, L. Dawson
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
The current advancements in new direct-acting antivirals such as sofosbuvir and others are so effective that shorter courses of therapy are associated with high sustained HCV response rates with relatively few toxicities.
The Management of Hepatocellular Carcinoma
Surgical resection is unequivocally the gold-standard treatment for early stage patients with unresectable HCC and there is renewed hope for the discovery of additional targeted therapies to treat tumor recurrence and allow for precision oncology approaches to patients with this deadly malignancy.
Treatment of intermediate-stage hepatocellular carcinoma
Current approaches used to accurately stratify patients with intermediate-stage HCC and subsequently allocate the most-appropriate treatments are reviewed and radioembolization is a promising alternative that deserves further prospective studies.
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
A comprehensive overview of the outcomes after liver transplantation for HCC, focusing on tumour recurrence in terms of surveillance, prevention and treatment is provided.
Radiofrequency Ablation for the Local Management Treatment of 1 Hepatocellular Carcinoma : Technical Aspects and Outcomes
Radiofrequency ablation should be part of the armamentarium of all physicians managing patients with HCC, and should be used in combination with other treatment modalities to provide an adequate ablation bed for large tumors.
Management strategies for hepatocellular carcinoma: old certainties and new realities
HCC treatment outcomes are affected by several variables, including liver function, patient’s performance status, and tumor stage, and the increasing knowledge of the genomic landscape of HCC and the development of molecular-targeted therapies is heading toward expanding the armamentarium for HCC management.
Management of Hepatocellular Carcinoma: Updated Review
An updated comprehensive review of the different aspects of liver cancer management starting from staging systems to the different applied treatment modalities is provided.
Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma
In this largest Western series of actual 10-year survivors after HCC resection, almost one in four patients survived over a decade, even though nearly half of this subset had developed recurrence.
Hepatocellular carcinoma: Therapeutic strategy in 2017
The Barcelona Clinic Liver Cancer staging system is the most accepted staging system, which has been externally validated, takes into account the most relevant prognostic parameters, and suggests the treatment approach based on the best scientific evidence.
Screening for hepatocellular carcinoma: patient selection and perspectives
The development of tools to enhance ability in optimizing available surveillance is likely to improve the prognosis of patients with HCC, and possible means of improvement are discussed.


In patients with early-stage hepatocellular carcinoma, liver transplantation was more effective than resection of the liver, and in patients with late-stage tumors, tumor–node– metastasis status, the number of tumors, the serum alphafetoprotein concentration, treatment received before transplantation, and 10 other variables were not significantly correlated with survival.
Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic
Surveillance for HCC identified patients with smaller tumor burdens and more adequate liver function who were able to receive more definitive therapies and should be included as standard of care for patients with hepatitis B.
Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma
Univariate analysis revealed that tumor size, tumor number, alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and Lens culinaris agglutinin-reactive fraction of alpha- Fetoprotein were significant risk predictors of vascular invasion.
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study.
Clinical differences between HCC patients diagnosed by surveillance and those with incidentally detected HCC are clarified, suggesting early detection of HCC by surveillance may contribute to a greater chance of receiving effective treatment and prolonged survival, although a further prospective, randomized study is needed.
Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months: A 15-Year Prospective Study
Using a Cox regression model, Child-Pugh class, Japanese tumor-node-metastasis stage, and &agr;-fetoprotein levels were independently associated with patient survival.
Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
In a mixed-aetiology cohort, the most effective surveillance strategy is to screen each patient with AFP assay and ultrasound imaging on a 6-monthly basis, and different surveillance strategies may provide the best value for money in patient groups of different cirrhosis aetiologies.
Design and endpoints of clinical trials in hepatocellular carcinoma.
These guidelines provide a common framework for designing trials to facilitate comparability of results, and randomized phase 2 trials with a time-to-event primary endpoint, such as time to progression, are pivotal in clinical research on HCC.